Publications
Bowen DJ, Shinn EH, Gregrowski S, Kimmick G, Dominici LS, Frank ES, Smith KL, Rocque G, Ruddy KJ, Pollastro T, Melisko M, Ballinger TJ, Fayanju OM, Wolff AC. Patient-reported outcomes in the Translational Breast Cancer Research Consortium. Cancer. 2019. PMID: 31743427
Franc BL, Thombley R, Luo Y, Boscardin WJ, Rugo HS, Seidenwurm D, Dudley RA. Identifying tests related to breast cancer care in claims data. The breast journal. 2019. PMID: 31736191
Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA. Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019. PMID: 31732523
Owyong M, Chou J, van den Bijgaart RJ, Kong N, Efe G, Maynard C, Talmi-Frank D, Solomonov I, Koopman C, Hadler-Olsen E, Headley M, Lin C, Wang CY, Sagi I, Werb Z, Plaks V. MMP9 modulates the metastatic cascade and immune landscape for breast cancer anti-metastatic therapy. Life science alliance. 2019. PMID: 31727800
Chari A, Vogl DT, Jagannath S. Selinexor for Refractory Multiple Myeloma. Reply. The New England journal of medicine. 2019. PMID: 31722163
Le DT, Kim TW, Van Cutsem E, Geva R, Jäger D, Hara H, Burge M, O'Neil B, Kavan P, Yoshino T, Guimbaud R, Taniguchi H, Elez E, Al-Batran SE, Boland PM, Crocenzi T, Atreya CE, Cui Y, Dai T, Marinello P, Diaz LA, André T. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019. PMID: 31725351
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic oncology. 2019. PMID: 31734020
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic oncology. 2019. PMID: 31734020
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, Mucci L, Parsons JK, Saad F, Soule H, Morgans A, Ryan CJ. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic oncology. 2019. PMID: 31734020
Courtney D. DiNardo, Rebecca Olin, Jo Ishizawa, Hiroyuki Sumi, Jingdong Xie, Kazunobu Kato, Prasanna Kumar, Michael Andreeff. A Phase 1 Dose Escalation Study of Milademetan in Combination with 5-Azacitidine (AZA) in Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS). Blood. 2019. PMID:
Jordon Jaggers, Heidi D. Klepin, Tanya M. Wildes, Rebecca L. Olin, Andrew S. Artz, Sarah A Wall, Samantha Jaglowski, Basem M. William, Don M. Benson, Ashley E. Rosko. Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. Blood. 2019. PMID:
Rebecca L. Olin, Caitrin Fretham, Marcelo C. Pasquini, Mukta Arora, Vijaya R. Bhatt, Benjamin Derman, Sergio A Giralt, Li-Wen Huang, Thuy T. Koll, Sang Mee Lee, Richard J Lin, Linda Pang, Uday Popat, Daniel J. Weisdorf, Andrew S. Artz. Cognitive Impairment Is Associated with Inferior Survival and Increased Non-Relapse Mortality in Older Allogeneic Hematopoietic Cell Transplant (alloHCT) Recipients: A Multicenter Retrospective Study. Blood. 2019. PMID:
Benjamin Demaree, Cyrille Delley, Cheryl Peretz, Harish Vasudevan, David Ruff, Aik Ooi, Catherine C. Smith, Adam Abate. Combined Single-Cell DNA Genotyping and Protein Quantification (DAb-seq) in Acute Myeloid Leukemias Reveals Distinct Immunophenotypic Subsets Among Pathogenic Clones. Blood. 2019. PMID:
CHI-HENG WU, Chen-Yen Yang, Linlin Wang, Hua-Xin Gao, Rakhshandehroo Taha, Shervin Afghani, Laura Pincus, Ronald Balassanian, James Rubenstein, Ryan Gill, Sourav Bandyopadhyay, Frank McCormick, Mark Moasser, Weiyun Z. Ai. Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models. Blood. 2019. PMID:
Amy Burd, Ross L. Levine, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael W. Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark Litzow, James M. Foran, Tara L. Lin, Brian J Ball, Michael Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison R. Walker, Vu H. Duong, Robert H. Collins, Nyla A. Heerema, Jo-Anne Vergilio, TIm Brennan, Christine Vietz, Molly Vittorio, Leonard Rosenberg, Sonja Marcus, Ashley Owen Yocum, Mona Stefanos, Brian J. Druker, John C. Byrd. Precision Medicine Treatment in Older AML: Results of Beat AML Master Trial. Blood. 2019. PMID:
Kelly L. Schoenbeck, Giselle Salmasi, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Aaron C. Logan, Rebecca L. Olin, Andrew D. Leavitt, Catherine C. Smith. Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms. Blood. 2019. PMID:
David A. Solomon, Huimin Geng, Raymond A. Sobel, Lakshmi Subbaraj, Mazie Tsang, James L. Rubenstein. Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies. Blood. 2019. PMID:
Naval G. Daver, Jacqueline S Garcia, Brian A Jonas, Kevin R Kelly, Sarit Assouline, Joseph M Brandwein, Pierre Fenaux, Rebecca L. Olin, Giovanni Martinelli, Stefania Paolini, Arnaud Pigneux, Daniel A Pollyea, Bayard L Powell, Gail J. Roboz, Agostino Tafuri, Norbert Vey, Giuseppe Visani, Karen W.L. Yee, Monique Dail, Cherie Green, Whitney P Kirschbrown, Wan-Jen Hong, Marion G Ott, Maika Onishi, Jue Wang, Marina Y Konopleva, Michael Andreeff. Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy. Blood. 2019. PMID:
Kelly L. Schoenbeck, Giselle Salmasi, Miguel Carlos Cerejo, Patricia A. Cornett, Lloyd E. Damon, Aaron C. Logan, Rebecca L. Olin, Andrew D. Leavitt, Catherine C. Smith. Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms. Blood. 2019. PMID:
Varun Mittal, Mimi Lo, Lloyd E. Damon, Karin L. Gaensler, Thomas G. Martin, Rebecca L. Olin, Catherine C. Smith, Aaron C. Logan. Efficacy of Venetoclax Combination Therapy with Hypomethylating Agents in Patients with Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation. Blood. 2019. PMID: